Vericel (NASDAQ:VCEL) PT Raised to $26.00

Vericel (NASDAQ:VCEL) had its price target hoisted by HC Wainwright from $22.00 to $26.00 in a report published on Thursday morning, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

Several other equities analysts have also commented on the company. SVB Leerink upped their target price on Vericel from $20.00 to $30.00 and gave the company an outperform rating in a research note on Monday, October 12th. BTIG Research upped their target price on Vericel from $21.00 to $23.00 and gave the company a buy rating in a research note on Wednesday, September 23rd. ValuEngine upgraded Vericel from a hold rating to a buy rating in a research note on Monday, October 12th. Oppenheimer restated a buy rating and set a $32.00 price target on shares of Vericel in a research note on Monday, October 5th. Finally, Truist initiated coverage on Vericel in a research note on Thursday, September 17th. They set a buy rating and a $24.00 price target for the company. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $25.00.

Vericel stock opened at $20.68 on Thursday. The firm has a market capitalization of $935.77 million, a P/E ratio of -2,068.00 and a beta of 2.88. The stock has a fifty day moving average price of $18.37 and a 200 day moving average price of $15.36. Vericel has a 52 week low of $6.78 and a 52 week high of $22.26. The company has a current ratio of 6.39, a quick ratio of 5.92 and a debt-to-equity ratio of 0.19.

Vericel (NASDAQ:VCEL) last released its earnings results on Wednesday, August 5th. The biotechnology company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.03. The business had revenue of $20.00 million during the quarter, compared to analyst estimates of $19.31 million. The business’s revenue for the quarter was down 23.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.05) earnings per share. As a group, equities analysts predict that Vericel will post -0.17 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. AJO LP purchased a new stake in shares of Vericel in the second quarter worth about $71,000. Private Advisor Group LLC purchased a new stake in shares of Vericel in the second quarter worth about $73,000. Invesco Ltd. purchased a new stake in shares of Vericel in the first quarter worth about $100,000. Jane Street Group LLC purchased a new stake in shares of Vericel in the first quarter worth about $104,000. Finally, Advisory Services Network LLC boosted its position in shares of Vericel by 623.3% in the second quarter. Advisory Services Network LLC now owns 10,850 shares of the biotechnology company’s stock worth $150,000 after buying an additional 9,350 shares during the period. 94.98% of the stock is owned by institutional investors.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Featured Story: Diversification Important in Investing

The Fly

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.